Characteristics of patients by cholecystitis-related complications

CharacteristicComplications(n = 6)No complications(n = 19)
ICI type, n (%)
 Anti–CTLA-41 (17)7 (37)
 Anti–PD-1/L13 (50)12 (63)
 Combination2 (33)0 (0)
Months from ICI to onset, median (IQR)7 (1–10)5 (0.1–31)
Positive infectious workup, n (%)2 (33)0 (0)
Peak biochemistry values, median (IQR)
 White blood cell count, cells/L11 (5–16)6 (1–33)
 Total bilirubin, mg/dL1.5 (0.7–3.9)1.3 (0.4–36.1)
 Direct bilirubin, mg/dL0.9 (0.2–3.5)1.1 (0.2–33.4)
 Alkaline phosphatase, IU/L169 (34–579)167 (61–1281)
 ALT, IU/L39 (19–364)62 (12–296)
Hospitalization, n (%)5 (83)10 (53)
Intravenous fluid, n (%)6 (100)11 (58)
Antibiotics, n (%)6 (100)12 (63)
Surgical treatment, n (%)5 (83)6 (32)
Duration of symptoms in days, median (IQR)9 (5–17)4 (1–14)
Restarted ICI therapy, n (%)2 (33)8 (42)

ICI immune checkpoint inhibitor, IQR interquartile range, CTLA-4 cytotoxic T-lymphocyte associated antigen 4, PD-1/L1 programmed cell death protein 1 or its ligand, ALT alanine aminotransferase